drugset
drugset / Trial / NCT05602727

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

NCT05602727 ↗

Phase 2 Terminated 99 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.

Timeline

Start
2022-12-02
Primary completion
2023-09-27
Completion
2023-09-27

Outcome

Missed primary endpoint

Stopped: “Voluntarily terminated due to benefit/risk assessment”

registry analysis (superiority test); MK-1942 5 mg vs Placebo; p = 0.186; LS Mean Difference 2.1 (97.5% CI -1.6 to 5.8); Longitudinal ANCOVA NCT05602727 ↗

registry analysis (superiority test); MK-1942 15 mg vs Placebo; p = 0.400; LS Mean Difference -1.4 (97.5% CI -5.2 to 2.4); Longitudinal ANCOVA NCT05602727 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-1942 Unknown 5 mg Oral
Subject MK-1942 Unknown 15 mg Oral

Indications

Alzheimer disease